REGENXBIO Settles ELEVIDYS Patent Litigation, Secures $39M Payment from Sarepta
RGNX sits 40% above its 52-week low of $5.455.
Summary
REGENXBIO settled all patent litigation with Sarepta over ELEVIDYS, receiving $39.0 million in cash and releasing infringement claims related to AAVrh74-based capsid products.
Key Events · Legal and Risk Events · RGNX
-
Patent Litigation Settlement
A Settlement Agreement among REGENXBIO, UPenn, Sarepta, and Catalent resolves all infringement litigation over the '617 and '274 patents related to ELEVIDYS.
-
$39M Cash Payment
Sarepta will pay REGENXBIO $39.0 million within 10 days of the effective date, providing immediate non-dilutive capital.
-
Covenant Not to Sue
REGENXBIO and UPenn released all current infringement claims and agreed not to sue over future claims relating to AAVrh74-based capsid products, including ELEVIDYS.
-
Scope of Release
The covenant does not extend to patents covering other aspects of gene therapy products, preserving REGENXBIO's broader intellectual property rights.
Analysis · RGNX · Life Sciences
The resolution of all patent infringement litigation with Sarepta Therapeutics over ELEVIDYS removes a major legal overhang for REGENXBIO. Under the settlement, Sarepta will pay $39.0 million in cash within 10 days, providing immediate non-dilutive capital at a time when the company faces an FDA clinical hold on RGX-121 and relies on its cash runway into Q4 2027. Importantly, the covenant not to sue covers only AAVrh74-based capsid products, leaving REGENXBIO's broader patent portfolio intact for other gene therapy applications.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGNX was trading at $7.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $495.1M. The 52-week trading range was $5.46 to $16.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.